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Abstract
Background: The drug discovery and development pipeline is a long and arduous process that inevitably hampers
rapid drug development. Therefore, strategies to improve the efficiency of drug development are urgently needed
to enable effective drugs to enter the clinic. Precision medicine has demonstrated that genetic features of cancer
cells can be used for predicting drug response, and emerging evidence suggest that gene-drug connections could
be predicted more accurately by exploring the cumulative effects of many genes simultaneously.
Results: We developed DeSigN, a web-based tool for predicting drug efficacy against cancer cell lines using gene
expression patterns. The algorithm correlates phenotype-specific gene signatures derived from differentially
expressed genes with pre-defined gene expression profiles associated with drug response data (IC50) from 140
drugs. DeSigN successfully predicted the right drug sensitivity outcome in four published GEO studies. Additionally,
it predicted bosutinib, a Src/Abl kinase inhibitor, as a sensitive inhibitor for oral squamous cell carcinoma (OSCC)
cell lines. In vitro validation of bosutinib in OSCC cell lines demonstrated that indeed, these cell lines were sensitive
to bosutinib with IC50 of 0.8–1.2 μM. As further confirmation, we demonstrated experimentally that bosutinib has
anti-proliferative activity in OSCC cell lines, demonstrating that DeSigN was able to robustly predict drug that could
be beneficial for tumour control.
Conclusions: DeSigN is a robust method that is useful for the identification of candidate drugs using an input
gene signature obtained from gene expression analysis. This user-friendly platform could be used to identify drugs
with unanticipated efficacy against cancer cell lines of interest, and therefore could be used for the repurposing of
drugs, thus improving the efficiency of drug development.
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Background
The drug discovery and development pipeline is a long
and arduous process, one that is resource-intensive and
time-consuming, making these the main barriers for
rapid drug development. Furthermore, the attrition rate
is high, underscoring the need to improve strategies in
drug development and in expanding the usage of already
approved drugs [1]. Fortunately, the availability of a large
pool of drugs provides convenient candidates for drug
repurposing, which can contribute to reducing the time
for finding new, effective chemotherapeutic strategies [2].
The current challenge is to develop discovery pipelines to
prioritize testing of already approved drugs, particularly in
cancers with limited chemotherapy options, such as oral
cancer [3]. Lessons from laboratory and clinical studies
have demonstrated that genetic features of tumours either
in the form of mutational data or gene expression signa-
tures could be used to predict response to targeted therap-
ies, and this has formed the basis of precision medicine
that is currently practised in the clinic [4–6]. To extend
on the advancements in our ability to characterize the
cancer genome to unprecedented depth, these information
can be used to link genetic features to drug response,
which affords an opportunity to systematize the testing of
drug candidates for expanding the spectrum of available
cancer drugs for treatment.
Since the late 1980s, the NCI-60 panel of cancer cell
lines has been used to systematically identify anti-cancer
compounds and more recently, to identify biomarkers of
response [7, 8]. In 2012, the repertoire of cancer cell lines
used was expanded substantially with the inclusion of new
data from the Genomics of Drug Sensitivity in Cancer
(GDSC) and Cancer Cell Line Encyclopedia (CCLE) pro-
jects where 707 and 860 cancer cell lines respectively were
assembled for anti-cancer drug testing. Uniquely, more
than 13 cancer types are represented in these panels, and
more importantly, these cell lines are well-characterised
with respect to their gene expression and mutational
information [9, 10]. Additionally, more than 50% of these
cell lines were subjected to high-throughput drug screen-
ing and their response to a large panel of drugs have been
documented systematically [9, 10].
The development of computational tools that could take
advantage of the availability of high throughput gene
expression data to mine patterns of association between
drug sensitivity and gene expression signatures began with
the seminal work by Lamb et al. who developed the Con-
nectivity Map (CMap) algorithm [11]. Subsequently, other
bioinformatics tools were developed. For example, NFFin-
der searches for relationships between drugs, diseases and a
phenotype of interest using transcriptomic data as input
[12]. Using the same concept, the drug-to-protein associa-
tions were evaluated by the DMAP tool that resulted in the
formation of 438,004 drug-to-protein effect relationships
[13]. The Functional Module Connectivity Map (FMCM),
which extends CMap by constructing a functional network
of a set of differentially expressed genes, showed validation
results for four drugs that could affect cell viability in colo-
rectal cancer cell lines [14].
While GDSC provides large amounts of drug response
data from arrays of cell lines, additional analyses are needed
to extrapolate drug efficacy to new datasets. For example,
GDSC shows that the head and neck cancer cell lines FADU
and HSC-3 are reported to respond to the heat shock pro-
tein 90 (Hsp90) inhibitor 17-AAG [9]. However, predicting
which inhibitors are likely to be efficacious in new cell lines
derived from cancer patients remains a challenge.
To exploit the GDSC data for predicting drug sensitiv-
ity, we developed DeSigN (Differentially Expressed Gene
Signatures - Inhibitors), a CMap-inspired [11] bioinfor-
matics pipeline that enables gene expression patterns
from experimental data to be linked to gene expression
patterns associated with drug response in a cancer cell
line database. To demonstrate proof-of-concept of the
practical usefulness of DeSigN, we conducted two valid-
ation experiments. The first involves the examination of
reported efficacy of drug candidates against four differ-
ent cancer cell lines that are prioritized by DeSigN. The
second is an experimental validation of the sensitivity of
a set of oral squamous cell carcinoma (OSCC) cell lines
to bosutinib, a Src/Abl kinase inhibitor that is currently
used for treating leukemia but predicted by DeSigN to
be effective against OSCC cell lines.
Methods
Differentially Expressed Gene Signatures - Inhibitors
(DeSigN) platform
DeSigN is a web-based bioinformatics tool for associating
gene signatures with drug response phenotype based on
IC50 data, with the aim of identifying novel drugs that
have good potential to be repurposed for cancer therapy.
The DeSigN algorithm (Fig. 1) consists of three key
components: (i) a reference database that contains a set of
pre-defined gene expression profiles associated with drug
response data to 140 drugs; (ii) a set of differentially
expressed gene (DEG) signatures as query input and (iii) a
pattern-matching algorithm for evaluating similarity be-
tween the query gene signature and drug-associated gene
expression profiles in the reference database.
Reference database
We built the reference database using baseline microarray
data and drug sensitivity data obtained from the Genomics
of Drug Sensitivity in Cancer (GDSC) project. We first
downloaded the raw CEL microarray data files of solid
tumour cell lines from GDSC [9] (normalized using the
MAS5 algorithm). The probe sets were collapsed to gene
symbols using Gene Set Enrichment Analysis [15] with
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HT HG-U133A chip as reference, this process resulted in
12,772 unique genes. For each drug, we classified the can-
cer cell lines’ drug response phenotype (resistant or sensi-
tive) in the following way. We first ranked the cell lines by
their IC50 values (lowest to highest). Cell lines with IC50
that were U standard deviations larger than the median
IC50 of all cell lines were considered to be resistant; those
that were L standard deviations smaller were considered
to be sensitive. We chose the parameters U and L carefully
on a case-by-case basis. These two cut-offs were generally
values where sharp transitions in IC50 were observed in
the scatter plot of –log10(IC50) against rank. About 20 cell
lines each from the sensitive and resistant phenotype were
thus defined. The list of sensitive and resistant cell lines
defined for the 140 inhibitors in DeSigN is provided in
Additional file 1: Table S1. An example for the drug
Mitomycin-C is shown in Fig. 2.
Differential expression of microarray gene expression data
for the sensitive and the resistant phenotype was done using
the Linear Models for Microarray data (limma) algorithm
[16]. The result from limma for each inhibitor was sorted
and converted into ranked lists according to the gene’s mod-
erated t-statistic (rank 1 for largest value). This reference
database was used to connect the queries and return rank-
ordered list of inhibitors for a particular query (Fig. 1a).
Query signature
Differentially expressed genes (DEG) obtained from
microarray or RNA-Seq gene expression data of cell
lines of two different phenotype classes were used to
query DeSigN. DEGs were selected using joint filtering
of p-value and fold change [17], with threshold value set
at log2 fold change > 1 and p-value < 0.01 (Fig. 1b).
Pattern-matching algorithm
A pattern-matching algorithm based on the nonpara-
metric Kolmogorov-Smirnov (KS) statistic [11] was used
to associate query signatures to the drug-specific, rank-
ordered gene expression profile database. The KS test is
a rank-based pattern matching approach implemented in
the Connectivity Map [11], and its goal is to correlate in-
hibitors in GDSC that enrich for similar DEG based on
the IC50 drug sensitivity profiles.
The Connectivity Score is computed according to [11] as
follows. Let N be the total number of genes in the refer-
ence database, and T the number of genes in the query sig-
nature for up- or down-regulated genes. For every drug in
the reference database, we compute the rank-ordered
(using moderated t-statistic) list R for all N genes. Let j
index the query genes in such a way that R(j), the rank of
the j-th gene in the N total number of genes, is monotone
Fig. 1 Workflow of DeSigN. a A reference database of cell lines that are sensitive and resistant to drugs available in the GDSC database was
created. Version 1.0 contains 140 drugs with their unique ranked-based gene signatures. b Differential expressed gene signatures are generated
from differential expression analysis of cell lines from two distinct experimental conditions, e.g. cell line gene expression data from tumour sam-
ples versus normal samples. The up and down-regulated genes (log2 fold change > 1 and p-value < 0.01) thus selected will be used to query the
DeSigN database. c A ranked-based list of inhibitors is generated, with Connectivity Score between 1 (maximal efficacy) and −1 (minimal efficacy).
This allows users to prioritize the testing of these candidates
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increasing. For j = 1, 2, …,T, we compute the following two



















Subsequently, for each inhibitor i, the KS-like statistics
for up- and down-regulated query gene signature, ksup
i and
ksdown
i , are computed as (subscript omitted)
ksi ¼
a; if a > b;
0; if a ¼ b;
−b; if a < b:
8<
:
The Enrichment Score (ES1) for drug i in the reference
database is set to zero if both ksup
i and ksdown
i have the
same sign; otherwise, ESi = ksup
i − ksdown
i . The Connectiv-
ity Score (Si) for non-zero instances is a normalized













i and Q =miniES
i are the normalizing
constants.
DeSigN returns a ranked list of inhibitors that have the
highest Connectivity Score between the DEG and the
ranked-order gene expression profiles in the reference
database, with S ranging between 1 (maximal efficacy) and
−1 (minimal efficacy) (Fig. 1c).
To evaluate the statistical significance of Si, we used a
permutation approach to simulate the null distribution of
Si. Thus, m random gene sets, each having the same size
as the size of the input gene signature, were simulated.
Each gene set then yields Srandom
i (k), where k indexes the
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if Si ¼ 0;
8>>>>>>>>><
>>>>>>>>>:
where IA is the indicator function that takes the value 1 if
event A occurs, and 0 otherwise. Here, we set m = 1000.
The DeSigN web interface
The DeSigN website is freely available at http://design.can-
cerresearch.my/. Its web interface is implemented in PHP
(v7.0) with the support of jQuery (v1.4.2), and hosted using
the Apache Server. The reference database is generated and
managed using MySQL database (v5.5.49). DeSigN makes
use of the AJAX feature to quickly load content without
reloading the pages. All queries are sent to the Java-based
computing cluster to perform parallel computation. A help
document providing a guide for users to query and navigate
DeSigN is available in the website, with examples given.
Except the pattern-matching algorithm, which was pro-
grammed in Java and the Graphical User Interface (GUI),
which was built using PHP, the other methods were imple-
mented in R version 3.3.0.
Fig. 2 Example of –log10(IC50) rank plot to define drug response phenotype. The solid line represents the median IC50 values of inhibitor Mitomycin-C
whereas the lower and upper dashed lines represent the cut-off for classifying cell lines into sensitive or resistant phenotypes, respectively
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NCBI Gene Expression Omnibus (GEO) datasets
To demonstrate how DeSigN could be used to predict
candidate drugs, we used differentially expressed genes
generated from ER-positive breast cancer versus normal
tissue reported by Clarke et al. [18] that can also be
accessed from the NCBI Gene Expression Omnibus
(GEO) database under the accession number GSE42568.
In addition, four drug sensitivity studies published in the
NCBI GEO database were used to validate DeSigN
(Table 1). The microarray gene expression data from these
five GEO studies were subjected to differential analysis
using the GEO2R function provided by NCBI (version
info: R 2.14.1, Biobase 2.15.3, GEOquery 2.23.2, limma
3.10.1). For the four validation sets, we defined sensitive
cell lines as having IC50 < 1 μM and resistant cell lines as
having IC50 > 1 μM. The choice of these four studies was
guided by several inclusion and exclusion criteria. We in-
cluded studies where: (i) The median of the distribution of
gene expression values of each sample were more or less
equal; (ii) The subject of the drug sensitivity study was
Homo sapiens; (iii) Drug treatment was given for at least
48 h; (iv) Only one inhibitor was used. We excluded blood
cancer-related studies. For each study, a list of DEG was
identified and used to query DeSigN.
Cell culture
Five oral squamous cell carcinoma (OSCC; ORL-48, ORL-
150, ORL-156, ORL-196 and ORL-204) and three normal
oral keratinocyte (NOK) cultures previously developed in
our laboratory [19] were used to validate bosutinib, a drug
candidate predicted by DeSigN to be effective. The RNA-
Seq data of these cells were subjected to differential analysis
(OSCC versus NOK) using DESeq2 [19, 20]. DEG generated
from DESeq2 was used as the query signature in DeSigN to
shortlist candidate drugs for experimental validation.
All ORL cell lines and HSC-4 (sensitive control for re-
sponse to bosutinib) were cultured in Dulbecco’s Modified
Eagle Medium (DMEM)/F12 (1:1) supplemented with
10% (v/v) heat-inactivated fetal calf serum (FBS), 100 IU
Penicillin/Streptomycin and 0.5 μg/ml hydrocortisone as
described previously [19]. NOK were cultured in keratino-
cyte serum-free media (KSFM; GIBCO, Carlsbad, CA,
USA) supplemented with 25 μg/ml bovine pituitary extract,
0.2 ng/ml epidermal growth factor, 0.031 mM calcium
chloride and 100 IU Penicillin/Streptomycin (GIBCO,
Carlsbad, CA, USA) as described previously [19]. The breast
cancer cell line MCF7 (resistant control for response to
bosutinib) was cultured in RPMI 1640 medium (GIBCO,
Carlsbad, CA, USA) supplemented with 10% (v/v) heat-
inactivated FBS and 100 IU Penicillin/Streptomycin. All
cultures were incubated in a humidified atmosphere of 5%
CO2 at 37 °C.
Viability assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)
The effect of bosutinib on the selected OSCC cell lines was
determined using MTTassay with 1.5–8 × 103 cells per well
as described previously [19]. Cells were treated with 0.04–
5 μM of bosutinib, and cell viability was measured after
72 h of treatment. DMSO (0.5%) served as vehicle control.
The two-sample t-test was used to assess whether the
difference in the sample mean of IC50 between the tested
cell lines was statistically significant (p-value < 0.05). Experi-
ments were repeated at least three times.
Apoptosis assay
Apoptosis was quantified using a FITC Annexin V Apop-
tosis Detection Kit (BD Biosciences, San Jose, CA, USA) ac-
cording to the manufacturer’s instructions. Briefly, floating
and attached cells were collected at 24, 48 and 72 h after
bosutinib treatment at 1 μM, and then stained using FITC
Annexin V/Propidium iodide (PI). Apoptosis detection was
performed using BD FACSCANTO™ II flow cytometer and
data was analyzed using the BD FACSDiva™ software (BD
Biosciences, San Jose, CA, USA). For each of the three time
points, the two-sample t-test was used to test whether the
mean of total number of apoptotic events differed signifi-
cantly (p-value < 0.05) between bosutinib-treated cells and
the vehicle control (0.01% DMSO) cells. Experiments were
repeated at least two times.
Proliferation assay
The anti-proliferative effect of bosutinib on the OSCC cell
lines were examined using Click-iT EdU Cell Proliferation
Assay Kit (Invitrogen, Carlsbad, CA, USA) as previously
described [19]. The cell lines ORL-48, ORL-204 and ORL-
196 were treated with 0.3–3 μM bosutinib, for 24 h and cell
proliferation evaluation was based on 5-ethynyl-2′-deoxyuri-
dine (EdU) incorporation according to the manufacturer’s
protocol. Images were captured from 4 to 11 different fields
Table 1 GEO studies used to validate DeSigN prediction





GSE4342 Gefitinib Sensitive 17 12 GPL96 Coldren et al. [24]
GSE16179 Lapatinib Sensitive 3 3 GPL570 Liu et al. [35]
GSE9633 Dasatinib Sensitive 11 5 GPL571 Wang et al. [36]
GSE35141 Gemcitabine Resistant 6 6 GPL4133 Saiki et al. [37]
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of each treatment concentration and further analyzed using
EBImage [21]. The percentage of EdU-labelled cells was
expressed as the percentage of red fluorescent nuclei over
the total number cells reflected by DAPI-stained nuclei and
the data is presented as relative percentage compared to
control cells (0 μM). The two-sample t-test was used to test
whether the difference in the relative percentage of EdU+
cells differed significantly (p-value < 0.05) between treatment
and vehicle control for the three cell lines. Experiments were
repeated at least two times.
Results
Running DeSigN
To demonstrate how DeSigN can be used to generate a
list of prioritized candidate drugs, we tested differentially
expressed genes (DEG) generated from ER-positive breast
cancer cell line compared to normal tissues (GSE42568;
Fig. 3a) [18]. From the database (Fig. 3b), DeSigN returned
a list of 11 ranked inhibitors together with their target
proteins (Fig. 3c). Of note, the two top-scoring drugs,
AICAR and BIBW2992 are drugs that are actively being
studied as therapeutics against ER-positive breast cancer.
The drug AICAR, which targets AMPK, have shown to
have anti-proliferative effects in ER-positive breast cancer
cell lines [22]. Further, a Phase II clinical trial demon-
strated that BIBW2992 was able to induce stable disease
in more than 50% of ER-positive metastatic breast cancer
that has progressed on letrozole monotherapy when used
in combination with letrozole [23]. DeSigN also predicted
resistance of ER-positive breast cancer cells against drugs
with strong negative Connectivity Score such as dasatinib
and midostaurin. The list of DEG from GSE42568 used to
query DeSigN is provided in Additional file 2: Table S2.
Validation results
GSE4342 is a study that demonstrated the sensitive re-
sponse of 17 non-small cell lung cancer (NSCLC) cell
lines to gefitinib (EGFR-inhibitor) treatment [24]. By
querying DeSigN using 205 up- and 137 down-regulated
genes, two drugs - gefitinib and BIBW2992, were returned
with positive Connectivity Score (p-value < 0.05). As ex-
pected, gefitinib was returned as the top-ranked inhibitor
with Connectivity Score of 1.00 and p-value < 0.001
(Fig. 4). Interestingly, BIBW2992, also known as afatinib, a
second generation EGFR inhibitor, is ranked second with
a significant Connectivity Score of 0.93 (p-value = 0.021).
For each of the four studies, DeSigN returned Connect-
ivity Scores that correctly correlated drug response
outcome that was consistent with the respective published
GEO studies. In all these studies, DeSigN successfully
associated input gene signatures with the right drugs, all
with statistically significant p-values (Table 2). The list of
DEG of each study used to query DeSigN is provided in
Additional file 3: Table S3; Additional file 4: Table S4;
Additional file 5: Table S5 and Additional file 6: Table S6.
Using DeSigN to shortlist potentially efficacious inhibitors
for OSCC cell lines
As we demonstrated that DeSigN could correctly predict
drug response from published data, we next used DeSigN
to identify inhibitors that could control the growth of
OSCC cell lines. The gene signature for differential gene
Fig. 3 Example of a result page from DeSigN. Users can supply the differentially expressed genes for their study in the boxes in the Panel (a). Additional
information such as list of genes and drugs currently available in DeSigN can be found in Panel (b). Panel (c) shows the Connectivity Score results. Error
messages (e.g. invalid gene symbols or redundant gene symbol) are produced in Panel (d) to alert users of potential problems with input data
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expression between OSCC cell lines and NOK contained
69 and 86 up- and down-regulated genes (Additional file 7:
Table S7). Nine potentially efficacious drugs were returned
by DeSigN, with another five drugs were predicted to be
resistant (Fig. 5), with p-values < 0.05. The ranking results
corroborated well with recent findings. Two of the candi-
dates, BIBW2992 (ranked fourth) and bosutinib (ranked
eighth), have been recently reported to be effective against
head and neck squamous cell carcinoma (HNSCC) cell
lines [25]. We set out to further evaluate the efficacy of
bosutinib, which targets Src and Abl, as it is a recently
FDA-approved drug for treating BCR-ABL leukemic
patients and have no known effects against HNSCC or
OSCC, therefore the efficacy of bosutinib is unanticipated
when used against OSCC cell lines.
For experimental validation of bosutinib’s efficacy
against OSCC, we tested it in three OSCC cell lines (ORL-
196, ORL-204 and ORL-48). All three OSCC cell lines
(Table 3, Additional file 8: Figure S8) were found to have
significantly lower mean IC50 value compared to their
sensitive head and neck squamous cell carcinoma control
(HSC-4, IC50: 1.82 μM). Against the resistant control,
MCF-7, all three OSCC cell lines also had significant
lower mean IC50 (Table 3, Additional file 8: Figure S8).
This finding is supported by fluorescence-activated cell
sorting (FACS) analysis of the cells where bosutinib
induced cell death in OSCC cell lines in a time-dependent
manner (Fig. 6a, Additional file 9: Table S9). In particular,
ORL-196 cells were found to be more responsive to
bosutinib, as close to 35% of apoptotic cells were detected
as early as 24 h of treatment, while ORL-48 and ORL-204
remained unaffected. By 72 h, a significant number of
apoptotic cells (35–90%) were detected in all the OSCC
cell lines (p-values < 0.01), indicating the cytotoxic effect
of bosutinib in these OSCC cells.
Further confirmation from the Click-iT EdU cell prolif-
eration assay showed clearly that bosutinib inhibited the
proliferation of ORL-48, ORL-196 and ORL-204 cells as
demonstrated by the significant reduction in the number
of proliferating cells (red-stained cells) compared to the
non-treated cells (Fig. 6b). ORL-196 and ORL-204 dem-
onstrated growth inhibition of ~70–80% (p-value = 0.03,
n = 3; p-value = 0.049, n = 2 respectively) whilst ORL-48
showed growth inhibition of ~40% following bosutinib
treatment at 1 μM for 72 h (p-value = 0.04, n = 2) (Fig. 6c,
Additional file 10: Table S10 and Additional file 11: Figure
S11). The level of inhibition in the OSCC cell lines corrob-
orated well with their mean IC50 value for bosutinib.
Taken together, these biological observations demon-
strated that bosutinib confers anti-proliferative and cyto-
toxic effects in the tested OSCC cell lines.
Discussion
We have developed DeSigN, a web-based bioinformatics
tool that allows users to query large public database of
cancer cell line gene expression and drug response data
such as GDSC. We showed explicitly that querying
DeSigN using differentially expressed gene signatures
Fig. 4 DeSigN prediction result for GSE4342. Gefitinib is predicted to be sensitive, with significant Connectivity Score of 1.00 and p-value < 0.001
Table 2 NCBI GEO datasets validation summary
GEO reference Reported drug Expected drug sensitivity DeSigN rank DeSigN drug Target Connectivity Score p-value
GSE4342 Gefitinib Sensitive 1 Gefitinib EGFR 1.00 0.000
GSE16179 Lapatinib Sensitive 6 Lapatinib EGFR, ERBB2 0.87 0.015
GSE9633 Dasatinib Sensitive 6 Dasatinib ABL, SRC, KIT, PDGFR 0.83 0.025
GSE35141 Gemcitabine Resistant 129 Gemcitabine DNA replication −0.83 0.025
The Author(s) BMC Genomics 2017, 18(Suppl 1):934 Page 7 of 11
could reveal potentially efficacious candidate drugs, as
shown in the GSE4342 analyses. BIBW2992 (a newer
generation of EGFR inhibitor currently approved for
treating NSCLC patients who are refractory to gefitinib
and erlotinib), for example, could potentially replace
gefitinib, a first-generation EGFR tyrosine kinase inhibi-
tors (TKI) that is increasingly becoming a non-viable so-
lution as cancer cells of NSCLC patients treated with
gefitinib inevitably develop resistance and relapse, with
8–10 months of median time to progression [26–28]
To date, many cases of successful drug repurposing stud-
ies have been reported, an exemplary study being that of
methotrexate, a drug first developed for treating leukemia,
and subsequently repurposed to treat a wide spectrum of
cancers ranging from breast, ovarian, bladder to head and
neck cancers [29, 30]. Here, we demonstrated the success
of DeSigN in guiding the selection of bosutinib as a candi-
date drug against OSCC (a subset of HNSCC) cell lines.
Emerging evidence supports the possible use of bosutinib
for the treatment of HNSCC. First, the molecular target of
bosutinib, Src has been reported to be a frequently altered
gene in HNSCC and has been identified as a promising
drug target [31]. Second, an analysis of gene expression
data from 42 HNSCC cell lines also predicted that bosuti-
nib has anti-tumour effect on HNSCC [25]. To the best of
our knowledge this is the first time bosutinib was shown
experimentally to have potency in OSCC cell lines.
While tools such as NFFinder, DMAP and FMCM that
adopted the CMap concept make use of large public data-
bases such as GEO, DrugMatrix, STITCH and HAPPI as
their reference, DeSigN has its uniqueness whereby it expli-
citly capitalizes on the large panel of 707 human cancer cell
lines in GDSC that have well-characterized gene expression
and drug response data (Table 4). Specifically, DeSigN con-
structs drug-associated gene expression profile of resistant
and sensitive cell lines from these 707 cell lines, whereas
CMap associates response to a drug by constructing gene
expression profiles of pre- and post-treatment conditions
using only four cell lines. DeSigN utilizes the cumulative
gene expression effect of many genes rather than one or a
handful of genes, in this case global baseline DEGs. We
believe through pan-cancer approach as suggested by The
Cancer Genome Atlas (TCGA) Research Network, inherent
genetic similarities between human cancer cell lines could
result in the identification of relevant candidate drugs that
have hitherto not been tested [32].
The new leads derived from DeSigN are important for
accelerating the discovery of new drugs for HNSCC
treatment, which is currently limited to cetuximab,
where this drug remains the only FDA-approved tar-
geted therapy for advanced HNSCC [3]. Importantly, we
would like to emphasize that all candidates with positive
and significant Connectivity Score should be equally
considered for validation instead of considering just the
few top-ranked candidates, since factors such as cost of
drug, ease of availability, method of administering, side
Fig. 5 DeSigN prediction results for OSCC cell lines. Nine drugs were predicted to be efficacious (blue box) whereas five were predicted to have
minimal efficacy on the OSCC cell lines (red box)
Table 3 Mean IC50 relative to HSC-4 and MCF7 (μM)




ORL-196 (n = 4) 0.75 ± 0.03 5.8 1.9
ORL-204 (n = 3) 0.90 ± 0.04 3.6 1.9
ORL-48 (n = 5) 1.19 ± 0.05 4.1 1.9
HSC-4 (n = 3) 1.82 ± 0.03 - -
MCF7 (n = 3) 12.22 ± 1.32 - -
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effects and other factors, are important practical consid-
erations in the clinical setting.
The current implementation of DeSigN uses differen-
tially expressed genes as starting points to associate gene
signatures with drug response phenotype. This input is
not necessarily optimal, as genes that are involved in
dysregulated pathways in the pathogenesis of cancer may
not always have their expression substantially altered [33].
Since higher-order information such as network context
and post-translational modification including reversible
phosphorylation or acylation are not explicitly integrated
in the current version, future improvements to DeSigN
will focus on integrating these types of data.
For future work, we also intend to expand drug cover-
age in Version 1.0 of DeSigN by incorporating the gene
expression and drug response data from Cancer Thera-
peutics Response Portal (CTRP) [34] and other large-
scale pharmacogenomics studies. We anticipate that De-
SigN will evolve as more cell line gene expression and
drug response data become available.
Conclusions
DeSigN provides proof-of-concept for the feasibility of
using a computational approach to shortlist the most
promising drug candidates for effective drug repurposing
in cancer treatment. We expect that DeSigN will
continue to evolve based on usage feedback from the
community of cancer researchers, as well as improve-
ments in methods for mining gene signatures that have
strong network context.
Fig. 6 Differential sensitivity of OSCC cell lines, ORL-48, ORL-196 and ORL-204 to bosutinib. a Bosutinib induced apoptosis in OSCC cell lines.
ORL-48, ORL-196 and ORL-204 cells were treated with 1 μM of bosutinib for 24, 48 and 72 h followed by Annexin V/PI staining coupled with flow
cytometry analysis. The bars represent mean percentage of apoptotic cells ± SE of each cell line of at least two experiments. * denotes p-value <
0.05 relative to control cells. b Bosutinib inhibited the proliferation of OSCC cells as demonstrated by the reduced number of proliferating cells
(red stained cells) following 72 h treatment at 1 μM. The blue-stained nuclei represent the total number of cells in a field while the red-stained
nuclei represent proliferating cells that have incorporated the EdU label. c OSCC cell proliferation was significantly inhibited by bosutinib with
ORL-196 showing the greatest sensitivity (~80% inhibition) followed by ORL-204 (~70% inhibition) and ORL-48 (~50% inhibition) after bosutinib
treatment at 1 μM for 72 h. * denotes significance of p-value < 0.05
Table 4 Comparisons of tools that utilized Connectivity Map
concept
Tools Relationship feature Reference database
DeSigN Global baseline DEGs to drug
response
GDSC




DMAP Protein/gene to drug response STITCH and HAPPI
FMCM Pre- and post-treatment gene
expression to drug response
CMap
The Author(s) BMC Genomics 2017, 18(Suppl 1):934 Page 9 of 11
Additional files
Additional file 1: Table S1. List of sensitive and resistant cell lines for
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Additional file 7: Table S7. Differentially expressed genes from OSCC
cell lines. (XLS 38 kb)
Additional file 8: Figure S8. Mean IC50 of each cell line from MTT
assay. The bars represent mean IC50 ± SE of at least three experiments.
(TIF 705 kb)
Additional file 9: Table S9. Mean apoptotic cells relative to control (%).
(XLS 40 kb)
Additional file 10: Table S10. Mean EdU+ cells relative to control (%).
(XLS 47 kb)
Additional file 11: Figure S11. Bosutinib significantly inhibits the
proliferation of OSCC cells in dose-dependent manner. OSCC cell lines were
treated with bosutinib at 0.3–3 μM for 72 h and the effect of bosutinib on
cell proliferation was determined by Click-iT cell proliferation assay. *
denotes p-value < 0.05 relative to control untreated cells (0 μM). (TIF 785 kb)
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